Drug intelligence / Profile preview

KB17A

Development stage: Preclinical
Lead developer: KBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

KB17A is a monoclonal antibody developed by KBio Inc. It acts as an HLA-G inhibitor, primarily targeting neoplasms. HLA-G is a major histocompatibility complex class I molecule involved in immune tolerance, particularly in cancer and pregnancy. KB17A is currently in the preclinical phase of development.

Other names: KB17AKB-17AKB 17A

Targets

HLA-G (Human leukocyte antigen G)

Beyond the preview

Go deeper on KB17A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KB17A.

Explore the full profile